Robert Pace, MD
Family Medicine · Waldorf, MDNPI 1326030040
Payments from drug & device makers
Across 118 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$214
- Novo Nordisk$204
- Sanofi-aventis U.S. LLC$175
- Merck$168
- Boehringer Ingelheim$143
- Astellas Pharma US Inc$134
- plus $926 from 20 others
What the payments were for
- Food & beverage$1,90297%
- Education$613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $214 |
| Novo Nordisk | 14 | $204 |
| Sanofi-aventis U.S. LLC | 12 | $175 |
| Merck | 15 | $168 |
| Boehringer Ingelheim | 7 | $143 |
| Astellas Pharma US Inc | 5 | $134 |
| Pfizer | 11 | $131 |
| E.r. Squibb & Sons, L.L.C. | 3 | $130 |
| AbbVie(2 entities) | 7 | $105 |
| Amgen | 4 | $68 |
| Lilly USA, LLC | 4 | $59 |
| Sanofi Pasteur Inc. | 3 | $56 |
| Genentech USA, Inc. | 2 | $51 |
| GSK | 3 | $50 |
| EMD Serono, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $29 |
| Novartis | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $17 |
| Biogen | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,963 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $82,833 |
| OzempicSemaglutide | 52 | $50,403 |
| JanuviaSitagliptin Phosphate | 47 | $47,260 |
| MyrbetriqMirabegron | 38 | $29,443 |
| RybelsusSemaglutide | 17 | $24,820 |
| XareltoRivaroxaban | 25 | $22,989 |
| MounjaroTirzepatide | 16 | $19,251 |
| JardianceEmpagliflozin | 14 | $16,826 |
| TrulicityDulaglutide | 19 | $16,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,035 |
| FarxigaDapagliflozin Propanediol | 12 | $15,654 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $14,539 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $13,146 |
| LinzessLinaclotide | 20 | $9,563 |
| Chlorpromazine Hcl | 11 | $9,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $82,83383 claims |
| Novo NordiskOzempic, Rybelsus | $204 | $75,22469 claims |
| MerckJanuvia, Janumet | $168 | $60,40662 claims |
| Lilly USA, LLCMounjaro, Trulicity | $59 | $35,47735 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $29,44338 claims |
| Johnson & JohnsonXarelto | $29 | $22,98925 claims |
| AstraZenecaFarxiga, Symbicort | $214 | $18,04423 claims |
| Boehringer IngelheimJardiance | $143 | $16,82614 claims |
| GSKTrelegy Ellipta | $50 | $16,03512 claims |
| AbbVieLinzess, Lumigan | $105 | $15,62438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Waldorf
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.